Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,419,026

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?

by Zacks Equity Research

Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.

Zacks Equity Research

Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.

Zacks Equity Research

Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.

Zacks Equity Research

Globus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Why Globus Medical (GMED) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Globus Medical (GMED) Gains From NuVasive Buyout, Innovation

by Zacks Equity Research

Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

GMED or ABCM: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMED vs. ABCM: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Buy Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.

Zacks Equity Research

Globus Medical (GMED) Launches NuVasive's NSO in Global Market

by Zacks Equity Research

Globus Medical's (GMED) Precice Bone Transport is a less intrusive treatment that reduces complications for both the patient and the surgeon and is designed for various bone abnormalities.

Zacks Equity Research

Globus Medical (GMED) Completes NuVasive Merger Agreement

by Zacks Equity Research

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip

by Zacks Equity Research

According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.

Zacks Equity Research

Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings

by Zacks Equity Research

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?